FDA Approves ARAZLO (Tazarotene) Lotion For Acne Vulgaris

FDA Approves Ortho's New Acne Topical

The U.S. Food and Drug Administration has approved the New Drug Application for Ortho Dermatologics’ ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. ARAZLO is the first tazarotene acne treatment available in a lotion form, and has been shown to provide strong efficacy with favorable tolerability.